Open access · CC-BY
via OpenAlex
Quercetin as a Multi-Target Therapeutic Candidate in Amyotrophic Lateral Sclerosis: From Molecular Mechanisms to Nano-Delivery and Senolytic Strategies
Dr. Chamundeeswari M, R Senthilkumar S, Harini Shree S
INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · 2026
Mitochondrial dysfunction
Cellular senescence
Altered intercellular communication
Chronic inflammation
Senolytics
Human
Review
Abstract
Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that destroys motor neurons, leading to progressive paralysis and death usually within 2–5 years. Current drugs such as riluzole and edaravone offer only modest benefit, making new treatments urgently needed. Quercetin, a natural plant-derived flavonoid found in everyday foods, acts on multiple disease mechanisms at once — it fights oxidative stress, reduces neuroinflammation, prevents toxic protein clumping, protects mitochondria, and can even selectively destroy harmful senescent cells ("zombie" cells) that drive inflammation in the spinal cord. However, quercetin poorly dissolves in water, is rapidly broken down in the gut and liver, and barely crosses the blood-brain barrier (BBB). This review explains what makes quercetin scientifically promising for ALS, how nano-engineered drug carriers such as PLGA nanoparticles, lipid carriers, and exosomes can overcome these delivery problems, and how combining quercetin with the senolytic drug dasatinib might slow ALS progression. Key research gaps and steps needed before quercetin-based therapies can enter clinical trials for ALS patients are also discussed. Keywords: Amyotrophic lateral sclerosis; quercetin; neuroprotection; neuroinflammation; oxidative stress; TDP-43; SOD1; Nrf2/ARE; blood-brain barrier; nano-delivery; PLGA nanoparticles; senolytics(definition); senescence(definition); dasatinib; polyphenol; flavonoid
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.55041/ijsrem59557
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
M, D.C., S, R.S., & S, H.S. (2026). Quercetin as a Multi-Target Therapeutic Candidate in Amyotrophic Lateral Sclerosis: From Molecular Mechanisms to Nano-Delivery and Senolytic Strategies. <em>INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT</em>. https://doi.org/10.55041/ijsrem59557
Vancouver
M DC, S RS, S HS. Quercetin as a Multi-Target Therapeutic Candidate in Amyotrophic Lateral Sclerosis: From Molecular Mechanisms to Nano-Delivery and Senolytic Strategies. INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT. 2026. doi:10.55041/ijsrem59557.
BibTeX
@article{dr2026Querce,
title = {Quercetin as a Multi-Target Therapeutic Candidate in Amyotrophic Lateral Sclerosis: From Molecular Mechanisms to Nano-Delivery and Senolytic Strategies},
author = {Dr. Chamundeeswari M and R Senthilkumar S and Harini Shree S},
journal = {INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT},
year = {2026},
doi = {10.55041/ijsrem59557},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Molecular Biosciences 2024
Open access · CC-BY
Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS
International Journal of Molecular Sciences 2021
Open access · CC-BY
Nucleocytoplasmic Transport: Regulatory Mechanisms and the Implications in Neurodegeneration
Physiological Reviews 2018
Open access · OA
Blood-Brain Barrier: From Physiology to Disease and Back
Frontiers in Molecular Neuroscience 2020
Open access · CC-BY
Therapeutic Approaches Targeting Protein Aggregation in Amyotrophic Lateral Sclerosis
Cellular and Molecular Life Sciences 2024
Open access · CC-BY
Molecular hallmarks of ageing in amyotrophic lateral sclerosis
Stem Cells International 2017
Open access · CC-BY